Follow the people · Insider
Lorena Raquel Lerner
Lorena Raquel Lerner files insider transactions with the SEC as a chief scientific officer of Keros Therapeutics (KROS). We hold 2 disclosed purchases and sales filed since 20 February 2026, 1 of them in the last 90 days.
- Files forKROS
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure20 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 18 February 2026 — 18 August 2026Chief Scientific Officer · Keros Therapeutics (KROS)5 Form 4 lines · source: SEC Form 4
Everything they disclosed
5 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 3,568 shares of Keros TherapeuticsSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
- was granted 75,000 shares of Keros Therapeutics (a derivative holding)SEC Form 426 February 2026Employee Stock Option (Right to Buy) · traded 24 February 2026 · filed 26 February 2026
- was granted 75,000 shares of Keros Therapeutics (a derivative holding)SEC Form 426 February 2026Employee Stock Option (Right to Buy) · traded 24 February 2026 · filed 26 February 2026
- ▼ sold on the open market 3,873 shares of Keros TherapeuticsSEC Form 420 February 2026Common Stock · traded 18 February 2026 · filed 20 February 2026
- ▼ sold on the open market 3,873 shares of Keros TherapeuticsSEC Form 420 February 2026Common Stock · traded 18 February 2026 · filed 20 February 2026
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.